Skip to content
Methylcobalamin
Methylcobalamin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
B03: Antianemic preparations
B03B: Vitamin b12 and folic acid
B03BA: Vitamin b12 (cyanocobalamin and analogues)
B03BA05: Mecobalamin
HCPCS
No data
Clinical
Clinical Trials
175 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vitamin b 12 deficiencyD014806EFO_0000734E53.823241221
AnemiaD000740EFO_0004272D64.932339
Diabetic neuropathiesD003929EFO_10007831179
Cognitive dysfunctionD060825G31.841113
Chronic hepatitis cD019698EFO_0004220B18.2112
Iron-deficiency anemiaD018798HP_0001891D50112
Pregnancy rateD0188731112
Peripheral nervous system diseasesD010523G64112
Glucose intoleranceD018149HP_0000833R73.0311
OverweightD050177E66.311
Show 8 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228918411
T-cell lymphoma peripheralD016411C84.92314
Cardiovascular diseasesD002318EFO_0000319I98213
Myocardial infarctionD009203EFO_0000612I21123
Coronary artery diseaseD003324I25.11113
Lung neoplasmsD008175C34.90313
Type 2 diabetes mellitusD003924EFO_0001360E112213
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21233
StrokeD020521EFO_0000712I63.9213
Autistic disorderD001321EFO_0003758F84.02213
Show 23 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501214
Covid-19D000086382U07.1112
Head and neck neoplasmsD00625822
StomatitisD013280EFO_1001904K12.122
Nasopharyngeal neoplasmsD00930322
B-cell lymphomaD016393122
Coronary diseaseD00332711
Myocardial ischemiaD017202EFO_1001375I20-I2511
Heart diseasesD006331EFO_0003777I51.911
Neoplasm metastasisD009362EFO_000970811
Show 17 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Carpal tunnel syndromeD002349EFO_0004143G56.0123
T-cell lymphoma cutaneousD016410C84.A22
Colorectal neoplasmsD01517911
Pancreatic ductal carcinomaD02144111
Pancreatic neoplasmsD010190EFO_0003860C2511
Triple negative breast neoplasmsD06472611
AdenocarcinomaD00023011
Sezary syndromeD012751C84.111
Primary cutaneous anaplastic large cell lymphomaD054446C86.611
Mycosis fungoidesD009182C84.011
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients33
HyperhomocysteinemiaD02013822
Aphthous stomatitisD013281EFO_0003938K12.022
PregnancyD011247EFO_0002950Z33.122
DeliriumD003693R41.011
Liver cirrhosisD008103EFO_0001422K74.011
ScoliosisD012600EFO_0004273M4111
Vitamin d deficiencyD014808EFO_0003762E5511
Yin deficiencyD01671011
PapillomaviridaeD02738311
Show 24 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMETHYLCOBALAMIN
INNmecobalamin
Description
Methylcobalamin (mecobalamin, MeCbl, or MeB12) is a cobalamin, a form of vitamin B12. It differs from cyanocobalamin in that the cyano group at the cobalt is replaced with a methyl group. Methylcobalamin features an octahedral cobalt(III) centre and can be obtained as bright red crystals. From the perspective of coordination chemistry, methylcobalamin is notable as a rare example of a compound that contains metal–alkyl bonds. Nickel–methyl intermediates have been proposed for the final step of methanogenesis.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1=C2N=C(C=C3N=C(C(C)=C4[N-][C@H]([C@H](CC(N)=O)[C@@]4(C)CCC(=O)NC[C@H](C)OP(=O)([O-])O[C@@H]4[C@@H](CO)O[C@H](n5cnc6cc(C)c(C)cc65)[C@@H]4O)[C@]4(C)N=C1[C@@H](CCC(N)=O)[C@]4(C)CC(N)=O)[C@@H](CCC(N)=O)C3(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[CH3-].[Co+3]
Identifiers
PDB
CAS-ID13422-55-4
RxCUI29421
ChEMBL IDCHEMBL4297672
ChEBI ID
PubChem CID6436232
DrugBankDB03614
UNII IDBR1SN1JS2W (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,841 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
352 adverse events reported
View more details